Q4 2025 PDS Biotechnology Corp Earnings Call Transcript
Key Points
- PDS Biotechnology Corp (PDSB) has made significant progress in its clinical programs, particularly with the VERSATILE-003 trial amendment, which could lead to a more efficient path to accelerated approval.
- The company's investigational drug, PDS0101, shows promise as a treatment for HPV16-positive head and neck cancer, with compelling data from the VERSATILE-002 Phase II trial.
- Early results from the National Cancer Institute-led trial on PDS01ADC demonstrate encouraging progression-free survival and PSA declines in metastatic castration-resistant prostate cancer patients.
- PDS Biotechnology Corp (PDSB) has strengthened its intellectual property portfolio with new patents in the United States and Japan, extending market protection into the 2040s.
- The company has managed to reduce its net loss and operating expenses compared to the previous year, demonstrating financial discipline.
- PDS Biotechnology Corp (PDSB) reported a net loss of $34.5 million for the year ended December 31, 2025, indicating ongoing financial challenges.
- Research and development expenses remain high, although slightly reduced from the previous year, reflecting the significant costs associated with advancing clinical trials.
- The company's cash balance as of December 31, 2025, was $26.7 million, which may limit its financial flexibility moving forward.
- There is uncertainty regarding the exact enrollment target and sample size for the amended VERSATILE-003 trial, which could impact the trial's timeline and outcomes.
- The company has not provided specific financial guidance for 2026, creating uncertainty about future research and development expenses and overall financial performance.
Greetings, and welcome to the PDS Biotech fourth-quarter 2025 earnings call. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host, Mike Moyer with LifeSci Advisors. Thank you. You may begin.
Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's fourth-quarter 2025 results and clinical programs update call. I'm joined on the call today by the following members of the company's management team: Dr. Frank Bedu-Addo, Chief Executive Officer; Dr. Kirk Shepard, Chief Medical Officer; and Lars Boesgaard, Chief Financial Officer.
Dr. Bedu-Addo will begin with an overview of the company's recent highlights and its clinical development program. Dr. Shepard Will review the data and rationale behind the amendment the company recently adopted to its Phase III VERSATILE-003 trial, and Mr. Boesgaard will review the financial results for the quarter ended December 31, 2025. Following management's prepared
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
